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LinkersAntibody–drug conjugates (ADCs) consist of cytotoxic drugs covalently linked to monoclonal antibodies
directed to antigens differentially overexpressed in tumor cells. These loaded antibodies are expected to
selectively deliver lethal cargoes to tumor cells and provide sustained clinical beneﬁt to pre-selected can-
cer patients while, at the same time, minimizing systemic toxicity. Although on-target adverse events are
not completely avoided and the true efﬁcacy of these innovative agents still requires further clariﬁcation,
proof-of-concept has already been achieved in clinical settings with immunoconjugates containing
calicheamicin, auristatin or maytansine-based cytotoxic payloads. In this present article we review the
characteristics of the preceding cytotoxic platforms and their chemical conjugation approaches.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Cytotoxic drugs are broadly used to treat hematological malig-
nancies and solid tumors and, under certain clinical conditions,
have changed the natural course of some of these diseases. While
effective, due to their intrinsic mode of action, they may also cause
signiﬁcant on-target adverse events that could preclude their full
clinical efﬁcacy, possibly resulting in early discontinuation of med-
ication and a consequent increased risk of tumor relapse or recur-
rence. Efforts aimed at improving the quality of treatment of
cancer patients have focused on alternative methods to both main-
tain the effectiveness of chemotherapeutic drugs and minimize
systemic toxicity. Among these novel approaches, the conjugation
of cytotoxic agents to humanized antibodies (also known as Anti-
body–drug conjugates, ADCs) has begun to gain momentum
among the scientiﬁc and clinical development cancer community.
The durable clinical responses reported with brentuximab vedotin
(SGN-35: Seattle Genetics/Takeda)1 and trastuzumab emtansine
(T-DM1; Roche in partnership with ImmunoGen),2 which have
recently obtained regulatory approval, have profoundly changed
the outlook for this modality of cancer therapy (for recent review
articles on this topic, see3).
Several aspects including the target, the antigen, the antibody,
the linker and the cytotoxic payload, must be thoroughly investi-
gated and balanced in the design and synthesis of an ADC drug,
as well as evaluated within the context of the targeted cancer indi-
cation. The loaded-antibodies combine the unique targeting capa-
bilities of monoclonal antibodies to discriminate between normaland tumoral cells with the cancer-killing ability of highly potent
cytotoxic drugs (cellular IC50 values in the pM range). Antibodies
engineered to track a speciﬁc tumor antigen bind themselves to
the surface of cancer cells and, upon internalization and processing
within endosomes or lysosomes, the ADC drug releases its lethal
cargo (Fig. 1). Due to its highly targeted tumor antigen recognition
and expression requirements for effective internalization and pro-
cessing, the ADC drug is expected to provide a wider therapeutic
window than the parent cytotoxic payload attached to it.
This review article covers representative examples of cytotoxic
agents that have become mature platforms in the generation of
clinical candidates or marketed ADCs. As illustrated throughout
this manuscript, linker strategies became key in the development
of ADCs and a range of conjugated chemistries have been explored
and optimized to provide cleavable (e.g., hydrazine or disulﬁde)
and non-cleavable (e.g., thioether) options to modify lysine or cys-
teine side-chains of monoclonal antibodies in a non-selective man-
ner. As a result of this non-selective conjugation approach, the
synthetic ADC is a mixture of molecules that can have different
drug-antibody ratios (also known as DARs). Due to limitations of
space, we will not cover recent biotechnological advancements
directed to have site-speciﬁc conjugation sites to ﬁx the number
and precise location of attachment of linkers and cytotoxic pay-
loads (e.g., thio-engineered antibodies or non-natural amino acids
containing antibodies).4
The following sections are organized by the mechanism of
action of the selected cytotoxic agents: DNA- and tubulin-acting
payloads. We also brieﬂy review emerging cytotoxic platforms.
Doxorubicin is an anticancer agent belonging to the anthracy-
cline family. The compound was ﬁrst hemi-synthesized in the
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Figure 2. The chimeric anti-LewisY cBR96 mAb conjugated with doxorubicin.
Figure 1. Schematic representation of the processes associated to the mechanism of action and biological activity of Antibody drug conjugates.
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teria. Since its marketing approval in 1974, this chemotherapeutic
agent has been used in the treatment of several cancers including
hematological malignancies, carcinomas and soft tissue sarcomas.
To minimize its systemic toxicity, a hydrazone acid-labile doxoru-
bicin conjugated with the chimeric anti-LewisY cBR96 mAb was
investigated (Fig. 2). The acid-labile hydrazone linker relies onthe increased acidic environment of the endosomes (pH 5.5–6.2)
and lysosomes (pH 4.5–5.0) relative to systemic circulation (pH
7.4–7.5) to release the active drug. The potential advantages of
working with approved cytotoxic drugs, that is familiarity with
the human pharmacology and toxicology, did not pan out when
the ﬁrst conjugated doxorubicin ADC hit the clinic. In spite of the
compelling and promising preclinical data whereby the conjugated
doxorubicin cBR96-ADC was shown to be superior to free doxoru-
bicin, the ADC demonstrated only limited clinical therapeutic
activity and a narrow safety proﬁle.5 It was suggested that the
Fc-FccR-mediated antibody effector functions seen with the BR96
naked antibody could also play a role in the observed clinical tox-
icities. However, and in spite of the negative clinical results, the
hydrazone-based linker was validated as a potential option for
selectively connecting and releasing cytotoxic drugs to the desired
tumor cells. This linker strategy has also been exploited for other
payloads such as calicheamicin.
Calicheamicin (LL-E33288, Fig. 3) is a DNA-alkylating agent pro-
duced by Micromonospora echinospora ssp. calichensis and origi-
nally discovered in 1986 (American Cyanamid Co).6 The two
noticeable structural regions of the molecule (right and left hand
sites) play both distinct and speciﬁc biological roles. Thus, while
the aryltetrasaccharide moiety serves to deliver the drug to its tar-
get, the rigid bicyclic core that contains the enediyne warhead
Figure 3. Structure of calicheamicin.
Figure 4. Mechanism of action of calicheamicin.
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DNA cleavage properties (for a graphical representation of the
mechanism of DNA cleavage, see Fig. 4).
The described calicheamicin-based antibody conjugates are
disulﬁde versions of the trisulﬁde parent compound. Two coupling
strategies with N-acetyl-c-calicheamicin dimethyl hydrazide
(CalichDMH) have been reported to-date: (i) hydrazide; and (ii)
amide coupling. We have focused our attention exclusively on
the hydrazide-linker approach (Fig. 5).
Gemtuzumab ozogamicin (Wyeth), which was the ﬁrst ADC to
be approved by the US Food and Drug Administration in the year
20007 for use as second line therapy for the treatment of relapsed
acute myelocytic leukemia, is a representative example of acalicheamicin-based ADC (Fig. 4).3 Conjugation of CalichDMH to
surface-exposed lysines of the humanized anti-CD33 IgG4 j anti-
body (hP67.6) was accomplished using the 4-(40-acetylphenoxy)
butanoic bifunctional linker. This synthon forms an acyl hydrazine
linkage with the cytotoxic payload allowing a DAR value of around
two to three. Upon the internalization of the ADC, it is supposed
that the calicheamicin prodrug is released by hydrolysis of the
hydrazone bond. The enediyne drug is then activated by reductive
cleavage, presumably by glutathione, of the disulﬁde bond. In order
to prevent the premature release of calicheamicin by circulating
reduced thiols, the disulﬁde linkage is stabilized by two methyl
groups close to the disulﬁde bridge. Thus, the N-acetyl-c-caliche-
amicin dimethylhydrazide agent was attached to the antibody
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Figure 5. Representative example of an ADC loaded with calicheamicin.
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tuzumab ozogamicin was voluntary withdrawn from the market in
2010 by the sponsor due to safety concerns coupled with lack of
any shown clinical beneﬁt in a conﬁrmatory post-approval Phase
III clinical trial.
Inotuzumab ozogamicin (CMC-544, Pﬁzer) is another Calic-
hDMH-containing anti-CD22 IgG4 monoclonal antibody currently
undergoing Phase III clinical trials.3 CD22 is a glycoprotein that
belongs to the silalic-acid-binding immunoglobulin-like lectins
and is expressed in more than 90% of diffuse large B-cell Non Hodg-
kin lymphomas (DLBCL) and follicular lymphomas (FL). Although
this anti-CD22-targeting antibody utilizes the same hydrazine lin-
ker, the molecule (DAR = 6) appears to be more stable in systemic
circulation (1.5–2% hydrolysis per day over four days) than gem-
tuzumab ozogamicin. A randomized open-label Phase III clinical
trial comparing rituximab plus CMC-544 to rituximab plus gemcit-
abine or bendamustine in relapse/refractory aggressive B-cell NHL,
is ongoing.8 Additional clinical studies are evaluating CMC-544 in
acute lymphoblastic leukemia patients. The dose limiting toxicities
are thrombocytopenia and neutropenia.
The dolastatin series of pentapeptides, which were originally
discovered as constituents of the sea hare Dolabella auricularia,
have been structurally modiﬁed to provide closely related and
equipotent derivatives, also known as auristatins, suitable for clin-
ical development (e.g., dolastatin 10; Fig. 6) and antibody conjuga-
tion (e.g., monomethyl auristatin E and F; Fig. 6).9 These synthetic
agents interact with the Vinca alkaloid binding site on a-tubulin
and block its polymerization and prevent the formation of the
mitotic apparatus. Several auristatin based ADCs have beenO
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Figure 6. Structures of dolastatin 10 anevaluated in clinical settings, one of which, brentuximab vedotin
(SGN-35: Seattle Genetics/Takeda), received marketing approval
back in August 2011.1,10
CD30, which is a type II transmembrane protein belonging to
the Tumor Necrosis Factor family, is highly and selectively
expressed on the surface of Hodgkin Lymphoma (HL) and some
T-cell non-Hodgkin lymphomas (Tc-NHL) cancer cells. The chime-
ric anti-CD30 mAb cAC10, which induces growth arrest of CD30+
tumor cells, was covalently linked via cysteine residues to mono-
methyl auristatin E (MMAE) through a valine-citrulline dipeptide
linker and a para-aminobenzylalcohol (PABA) self-immolative
spacer (cAC10-mc-vc-PABA-MMAE; Fig. 7). The sulfhydryl groups
of the available cysteines on the antibody were liberated after a
mild reduction of the inter-chain disulﬁde bonds. The toxic pay-
load was shown to be stably attached to the antibody (2% release
of MMAE following 10-day incubation in human plasma), but
selectively cleaved by lysosomal enzymes (presumably cathepsin
B) after CD30 receptor-mediated internalization.11 Although the
expression of CD30 was required for activity, there was no direct
correlation between the level of expression of the antigen and sen-
sitivity to the ADC in cellular settings, indicating that multiple fac-
tors such as internalization, intracellular trafﬁcking or enzymatic
cleavage, determine tumor cell sensitivity. cAC10-vc-MMAE
(SGN-35) was selected as a candidate for clinical evaluation follow-
ing preclinical studies of the conjugate with two, four and eight
DARs evidencing that the conjugate with DAR = 4 provided the best
compromise between efﬁcacy and pharmacokinetic parameters.12
Brentuximab vedotin is currently approved for treating relapsed
or refractory Hodgkin’s lymphoma, as well as anaplastic large cellO
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Figure 7. Representative example of an ADC loaded with monomethyl auristatin E.
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SGN-35 demonstrated a complete remission rate of 34% in clinical
trials, while the complete remission rate in ALCL patients was
around 57%. The most severe adverse events described thus far
are neutropenia, peripheral sensory neuropathy, fatigue, and
hyperglycemia.
Other antibodies with MMAE targeting including CD22
(RG7593; Roche), NaPi2b (RG7599; Roche), anti-MUC16
(RG7458; Roche), PSMA (Progenics Pharmaceuticals) and the
tumor-associated glycoprotein NMB (CDX-011; Celldex Therapeu-
tics), are under clinical development, as are conjugates with mono-
methyl auristatin F (MMAF; e.g., PF-06263507, a 5T4-targeted
ADC; Pﬁzer), which are supposed to have lower toxicity, attenu-
ated potency and improved aqueous solubility relative to MMAE.
Interestingly, biologically active ADCs, such as anti-CD30 and
anti-LeY antibodies, have been generated by replacing the cleav-
able valine-citrulline dipeptide in MMAF with a non-cleavable thi-
oether linkage (structure not shown). Mass spectrometry revealed
the released drug to be a cysteine-adduct of the linker-MMAF
derivative. A similar linker replacement did not work with MMAE.
This experimental ﬁnding once more demonstrates the important
role of the linker and the nature of the cytotoxic agent and metab-
olites in the antitumor activity of ADCs.3
Maytansine (Fig. 8) is a benzoansamacrolide that was ﬁrst iso-
lated from the bark of the Ethiopian shrub Maytenus ovatus.13 This
cytotoxic agent and derivatives thereof bind to tubulin near the
Vinca alkaloid binding site. They are considered to have a high
afﬁnity for tubulin located at the ends of microtubules, yet lower
afﬁnity to sites distributed throughout the microtubules. The sup-
pression of microtubule dynamics causes cells to arrest in the G2/
M phase of the cell cycle, ultimately resulting in cell death by
apoptosis. Two maytansine derivatives—emtansine also referred
to as DM1; Figure 8, and ravtansine also referred to as DM4;
Figure 8-have been widely used in combination with irreversible
and reversible linkers. We have selected representative examples
to illustrate the current status of these two cytotoxic platforms.
ADCs containing non-disulﬁde-conjugated DM1 showed increased
pharmacokinetic plasma exposure in both rats and cynomolgusCl
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Figure 8. Structures of maymonkeys. This increase in drug exposure did not lead to an
increase in either target-dependent or -independent toxicity and
triggered the selection of a thioether linker in the synthesis of
the trastuzumab-based clinical candidate. Trastuzumab emtansine
(T-DM1; Roche in partnership with ImmunoGen),2 which received
marketing approval in 2013, is a human epidermal growth factor
receptor (HER2)-targeted antibody drug conjugate composed of
trastuzumab, a stable thioether linker, and the potent cytotoxic
agent DM1.14 The ﬁrst step of the conjugation involves reacting
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(SMCC) with the amino side chain of a lysine residue to form an
amide bond at pH 7–9 (Fig. 9). Subsequently, the maleimido moi-
ety undergoes a Michael type-addition with thiols at pH 6.5–7.5
to form thioether bonds with the cytotoxic agent resulting in an
average DAR value of 3.5. As shown in preclinical studies, the drug
combines the distinct mechanisms of action of both DM1 and
trastuzumab, and has antitumor activity in trastuzumab- and
lapatinib-refractory experimental human tumor models. It is
important to note that the catabolic degradation of the ADC in
the lysosome leaves a lysine residue on the maytansine derivative.
The catabolite is still biologically active, but, due to its positive
charge it is not able to cross the cellular membrane with
high efﬁciency, precluding its externalization, diffusion and ability
to kill surrounding cells. Clinically, T-DM1 has a consistent
pharmacokinetic proﬁle and minimal, albeit measurable, systemic
exposure to free DM1. T-DM1 has been approved as a second-line
treatment for breast cancer patients that have previously failed
to respond to therapy with trastuzumab and taxane-based
chemotherapy. In a Phase III clinical trial with around 1000
patients, T-DM1 was shown to improve median overall survival
by close to six months and progression-free survival by 50%
vis-à-vis lapatinib/capecitabine in combination. Thrombocytopenia,
peripheral neuropathy, anemia, increased transaminases, musculo-
skeletal pain, and constipation were adverse events more
frequently associated to T-DM1 than with the combined treatment.
SAR3419 (Sanoﬁ in collaboration with ImmunoGen) is another
representative example of a maytansine-based ADC.3 This drug is
composed of a humanized IgG1 monoclonal anti-CD19 antibodySH
Cl
N
O O
O H
OH
N
H
O
O
H
O
N
O
MeO
OMe
O H
OH
N
H
O
O
H
O
N
O
SH
Me
DM4
tansine, DM1 and DM4.
Figure 9. Generic structures of ADCs loaded with the SMCC-DM1 and SPDB-DM4 cytotoxic payloads.
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SPDB-DM4; Fig. 9). The disulﬁde bond provides a trigger that is sta-
ble in plasma, but releases DM4, presumably by glutathione, in the
reducing intracellular environment. The two germinal dimethyl
groups next to the disulﬁde bond serve to increase chemical stabil-
ity by sterically blocking the attack of the reducing agent. Contrary
to DM1, the DM4metabolites can cross the cellular membrane and,
upon diffusion, induce the extermination of surrounding cells, a
phenomenon known as a ‘bystander effect’. SAR3419 is in Phase
II clinical trials and has demonstrated a response rate of almost
60% in diffuse large B-cell lymphoma (DLBCL) patients treated with
a combination of SAR3419 and rituximab.
In addition to the monomethyl auristatins E and F, emtansine
and ravtansine conjugated ADCs that account for more than 80%
of current clinical candidates, other emerging cytotoxic platforms
are gaining prominence in this area of drug discovery. In the sec-
tion to follow we brieﬂy summarize the most advanced molecules
that will require further research and could potentially deliver ADC
candidates with novel mechanisms of action in the near future.
a-Amanitin, which is a toxin found in several species of the
Amanita mushrooms (e.g., Amanita phalloides), is a bicyclic octa-
peptide (Fig. 10) that inhibits RNA polymerase II by blocking the
translocation of RNA and DNA.15 The molecule can reduce the
enzymatic rate of polymerase II from several thousands to a few
nucleotides per minute, and has exhibited comparable toxicity
against proliferating and resting tumor cells. Sites in a-amanitin
that are suitable for linker integration without diminishing its bio-
logical activity have been identiﬁed and reducible disulﬁde and
protease-cleavage bridges have been optimized for ADC conjuga-
tion. Proof-of-concept in preclinical settings has been obtained
with several common targets. Thus, using trastuzumab as a carrier,
the corresponding ADC-DSC-a-amanitin conjugate exhibitedN
S
NH
N
H
NH
NH
NH
N
HN
H
N
H
O
OO
O
O
O
O
NH2
OH
OH
O O
O
H
OH
OH
H
Figure 10. Structure of a-amanitin.antiproliferative activity in erbB2-overexpressing tumor cell lines
at pM concentrations and tumor remission was observed after sin-
gle iv injection in the SKOV-3 and JIMT-1 s.c. human xenograft
models.16 At this point the safety proﬁle of a-amanitin conjugated
ADCs in clinical settings remains unclear, but, on the basis of
its intrinsic mechanism of action, we cannot rule out potential
on-target adverse events in the liver.
Naturally occurring pyrrolobenzodiazepines (PDBs) (Fig. 11)
containing molecules17 were originally isolated from various strep-
tomycin species. These natural products bind covalently discrete
sequences of base pairs in the minor groove of DNA, and it is
believed that the cross-link does not distort the DNA helix.18 The
binding activity of these agents interferes with DNA processes
including transcription and replication allowing them to act as
anti-tumor and antibiotic agents. A wide range of synthetic-
derived single or dimer PDB cytotoxic agents (e.g., SJG-136;
Fig. 11), have been recently generated and a few of them have
already reached clinical trials. Representative of these molecules
is SG-CD33A (Seattle Genetics; Fig. 12),19 which is currently
undergoing Phase I clinical trials for the treatment of acute
myeloid leukemia patients. In this case, the PBD-dimer is stably
and uniformly attached to two engineered cysteines of the
CD33-antibody using a proprietary linker technology. Although
few results on the use of PDB single or dimers as payloads in
ADC have been published to-date, the preclinical data showed that
these ADCs can achieve durable complete regression and
tumor free survival at tolerated doses. Of particular note is the
observation that the PDB dimers were not found to be cross-resistant
with widely-used chemotherapeutic agents.
Tubulysins20 are a new class of natural substances originally
isolated from the culture broth of strains of myxobacteria
Archangium gephyra and Angiococcus disciformis (Fig. 13). They
are distantly related to the dolastatins (Fig. 6), and are currently
among the most powerful cell division inhibitors known
(e.g., dolastatin-10 and tubulysin A are equally active). They canHO N
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Figure 11. Structures of natural pyrrolobenzodiazepine and a derivative thereof
(SJG-136).
Figure 12. Generic structure of an ADC loaded with a pyrrolobenzodiazepine payload.
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bule network of cells within 24 h. Moreover, tubulysin D, which is
the most active member of this family, can induce multipolar spin-
dles. They have been conjugated with polymers to provide proof-
of-concept in preclinical models and are now being further modi-
ﬁed to provide additional avenues for antibody or protein
conjugation.
It is reasonable to assume that future developments in the ADC
ﬁeld will seek to improve current manufacturing challenges and
lead to the identiﬁcation and validation of new cytotoxic platforms
aimed at providing more potent and safer drugs. Novel solutions to
site-speciﬁc linkers that offer improved stability and control the
number of cytotoxic agents bound to each antibody have pro-
gressed over the past few years and the ﬁrst molecule that exploits
the site-speciﬁc concept has already reached clinical trials (see, SG-
CD33A).21 These modiﬁcations, which also exploit the addition of
non-natural amino acids in the antibody,4 should have a positive
impact in simplifying downstream puriﬁcation processes. They
may however also signiﬁcantly increase the overall manufacturing
cost of ADCs.
Parallel to advances in manufacturing, innovative approaches to
increase the durability of clinical beneﬁt should also be further
explored. To this end, dual-warhead ADCs with two mechanisti-
cally different cytotoxic agents attached to the antibody may
address the challenge of drug resistance or lack of sensitivity
intrinsic to the heterogeneity of tumor tissues and allow the use
of the dual-cytotoxic ADC across different cancer indications. This
concept could also be used in the effective treatment of non-onco-
logical malignancies such as infectious diseases.
Although convincing clinical beneﬁt has already been observed
with ﬁrst generation ADCs, the current crop of ADCs will hopefully
conﬁrm the effectiveness of this modality and guide us to better
improve the identiﬁcation and development of such molecules.
The clinical results of these ADCs are eagerly anticipated.
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